column
Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021
Dan Wu, Yanyang Zhang, Lin Tang, Fuzhen Wang, Ying Ye, Chao Ma, Hui Zheng, Wenzhou Yu, Lei Cao, Yifan Song, Abuduwaili Reyimu, Xiaoxiao Zhang, Haifeng Wang, Yifei Nie, Mingxia Lu, Muge Qi, Jun Li, Ruolin Wang, Kaichao Yang, Changshuang Wang, Lawrence Everett Rodewald, Geroge Fu Gao, Zhijie An, Zundong Yin
2022, 4(4): 57-65. DOI: 10.46234/ccdcw2022.009
Abstract FullText HTML PDF
Willingness of the General Public to Receive A COVID-19 Vaccine Booster — China, April–May 2021
Xiaoxiao Wang, Leyuan Liu, Minyue Pei, Xiaoguang Li, Nan Li
2022, 4(4): 66-70. DOI: 10.46234/ccdcw2022.013
Abstract FullText HTML PDF
Bubble Strategy — A Practical Solution to Return to Regular Life in the Intertwined Era of Vaccine Rollouts and Virus Mutation
Ying Shen, Da Huo, Tong Yu, Quanyi Wang
2022, 4(4): 71-73. DOI: 10.46234/ccdcw2022.014
Abstract FullText HTML PDF
The Dynamic COVID-Zero Strategy in China
Jue Liu, Min Liu, Wannian Liang
2022, 4(4): 74-75. DOI: 10.46234/ccdcw2022.015
Abstract FullText HTML PDF
The First Two Imported Cases of SARS-CoV-2 Omicron Variant — Tianjin Municipality, China, December 13, 2021
Zhaolin Tan, Zhixiao Chen, Aiping Yu, Xiaoyan Li, Yenan Feng, Xiang Zhao, Wenbo Xu, Xu Su
2022, 4(4): 76-77. DOI: 10.46234/ccdcw2021.266
Abstract FullText HTML PDF